1477 Stock Overview
Operates as an ophthalmic pharmaceutical platform company in the People's Republic of China.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Ocumension Therapeutics Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$5.35 |
52 Week High | HK$8.75 |
52 Week Low | HK$4.51 |
Beta | 0.81 |
11 Month Change | -20.74% |
3 Month Change | -21.32% |
1 Year Change | -37.35% |
33 Year Change | -71.78% |
5 Year Change | n/a |
Change since IPO | -85.54% |
Recent News & Updates
Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results
Aug 15We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now
Jun 13Recent updates
Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results
Aug 15We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now
Jun 13Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable
Apr 29Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation
Mar 14Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates
Aug 29We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely
Jul 13Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?
Jun 02We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate
Jan 20We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate
Sep 27Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?
Jan 23Shareholder Returns
1477 | HK Pharmaceuticals | HK Market | |
---|---|---|---|
7D | -18.6% | -8.1% | 0.3% |
1Y | -37.4% | 4.0% | 4.0% |
Return vs Industry: 1477 underperformed the Hong Kong Pharmaceuticals industry which returned 4% over the past year.
Return vs Market: 1477 underperformed the Hong Kong Market which returned 4% over the past year.
Price Volatility
1477 volatility | |
---|---|
1477 Average Weekly Movement | 6.7% |
Pharmaceuticals Industry Average Movement | 5.3% |
Market Average Movement | 6.3% |
10% most volatile stocks in HK Market | 13.1% |
10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 1477's share price has been volatile over the past 3 months.
Volatility Over Time: 1477's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 444 | Victor Liu | www.ocumension.com |
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, blepharitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, acute glaucoma, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis.
Ocumension Therapeutics Fundamentals Summary
1477 fundamental statistics | |
---|---|
Market cap | HK$3.69b |
Earnings (TTM) | -HK$353.13m |
Revenue (TTM) | HK$339.53m |
10.9x
P/S Ratio-10.4x
P/E RatioIs 1477 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1477 income statement (TTM) | |
---|---|
Revenue | CN¥310.29m |
Cost of Revenue | CN¥129.44m |
Gross Profit | CN¥180.86m |
Other Expenses | CN¥503.58m |
Earnings | -CN¥322.73m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.47 |
Gross Margin | 58.29% |
Net Profit Margin | -104.01% |
Debt/Equity Ratio | 0% |
How did 1477 perform over the long term?
See historical performance and comparison